Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial

JAMA

Volumn 287, Issue 12, 2002, Pages 1531-1540

  Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NESIRITIDE; NITRATE; PLACEBO; WARFARIN;

ADULT; AGED; ARTERY CATHETERIZATION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HEMODYNAMICS; HUMAN; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; TREATMENT OUTCOME;

EID: 0037181511     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Guidelines for the evaluation and management of heart failure
2. The hospital course and short-term prognosis of patients presenting to the emergency room with de-compensated congestive heart failure
3. Intermittent, ambulatory dobutamine infusion in severe chronic cardiac failure
4. Xamoterol in severe heart failure
5. Effect of oral milrinone on mortality in severe chronic heart failure
6. Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure
7. Effects of vesnarinone on morbidity and mortality in patients with heart failure
8. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure
9. Sudden unexpected death in patients with congestive heart failure: A second frontier
10. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor?
11. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure
12. Brain natriuretic peptide
13. Coronary vasodilator effects of BNP
14. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure
15. Nesiritide therapy for decompensated CHF is not proarrhythmic
16. Renal effects of brain natriuretic peptide in patients with congestive heart failure
17. Subcutaneous administration of brain natriuretic peptide in experimental heart failure
18. Therapeutic potential of nesiritide (recombinant b-type natriuretic peptide) in the treatment of heart failure
19. Clinical pharmacokinetics of vasodilators, part II
20. Simulations of Pulmonary Capillary Wedge Pressure (PCWP) and Systolic Blood Pressure (SBP) with various regimens of nesiritide
21. Sustained beneficial effect of a seventy-two hour IV infusion of nitroglycerin in patients with severe chronic congestive heart failure
22. Comparison of the degree of hemodynamic tolerance during IV infusion of nitroglycerin versus nicorandil in patients with congestive heart failure
23. IV nitroglycerin tolerance in patients with ischemic cardiomyopathy and congestive heart failure
24. Sustained hemodynamic effects with therapeutic doses of IV nitroglycerin in congestive heart failure
25. Specialized delivery systems for intravenous nitroglycerin: Are they necessary?
26. The haemodynamic responses to incremental doses of intravenous nitroglycerin in left ventricular failure
27. Steady-state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure